FDA releases its latest batch of Warning Letters that includes one medical product company Bodyhealth.
U.S. Stem Cell tells an appeals court that its stromal vascular fraction procedure is not subject to FDA regulation under a 2001 FDA rule.
FDA accepts for priority review an Omeros BLA for narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.
FDA gives PMA approval to Seno Medical Instruments Imagio diagnostic breast cancer imaging technology.
FDA Review posts the Federal Register notices for the week ending 1/15/2021.
Federal Register notice: FDA reschedules a public meeting for 2/12 on Patient- Focused Drug Development for Vitiligo.
Federal Register notice: FDA announces a 4/7 virtual public meeting entitled Prescription Drug User Fee Act of 2017; Electronic Submissions and Data S...
Federal Register notice: FDA withdraws approval of 27 ANDAs from multiple applicants after they notified the agency that the drug products were no lon...